Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
Abemaciclib extends survival in early breast cancer
The combination of adjuvant abemaciclib and endocrine therapy (ET) significantly improves overall survival in patients with HR-positive, HER2-negative, node-positive, high-risk early breast cancer compared with ET alone, the phase III monarchE trial has shown.
Physical activity, especially walking, relieves fatigue in CRC survivors
A study presented at ASCO GI 2026 shows that colorectal cancer (CRC) survivors who remain physically active, particularly through walking, are less likely to experience severe fatigue and more likely to report better quality of life (QoL).
COMMIT: Triplet regimen extends PFS in select CRC patients
In the phase III COMMIT* trial, a combination of mFOLFOX6 (FFX), atezolizumab, and bevacizumab significantly improves progression-free survival (PFS) in patients with deficient mismatch repair or microsatellite instability-high metastatic colorectal cancer (dMMR/MSI-H mCRC).
NATALEE updates: Ribociclib benefit in HR+, ERBB– EBC sustained at 4 years
In an updated analysis of the NATALEE* trial, the efficacy benefit of adjuvant ribociclib remains consistent even after the planned 3-year treatment duration for patients with HR+, ERBB2– early breast cancer (EBC).
